Achillion to Present Updated Clinical and Preclinical Data on Multiple Compounds at AASLD 2011

NEW HAVEN, Conn., Oct. 3, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that four abstracts on HCV compounds discovered and developed by Achillion were accepted for presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD) to be held November 4-8, 2011 in San Francisco, CA.

During the congress, a poster presentation detailing Phase 2 segment 1 clinical trial results for ACH-1625, a once-daily protease inhibitor, will report updated 28-day safety and efficacy results for ACH-1625 administered in combination with pegylated-interferon and ribavirin for the treatment of treatment naïve genotype 1 HCV. Preclinical data on ACH-2684, a once-daily pan-genotypic protease inhibitor, as well as novel preclinical data for Achillion's second generation NS5A inhibitor compounds, will be reported during poster presentations at AASLD.

The Achillion data presentations at AASLD are as follows:

Date/Time Presentation Title
November 5
2:00 – 7:30 p.m.
Pharmacokinetic Modeling of ACH-2684, a Hepatoselective Phase I Pan-Genotypic HCV NS3 Protease Inhibitor: Predictions and Correlation with Human Pharmacokinetics
November 5
2:00 – 7:30 p.m.
Novel Hepatitis C Virus NS5A Inhibitors with Improved Potency against Genotype -1a Replicons and Replicons Carrying Mutations Associated with Viral Resistance to 1st Generation NS5A Inhibitors
November 5
2:00 – 7:30 p.m.
Combinatory Effect of Direct Anti-HCV Agents on Antiviral Efficacy and Viral Resistance in Genotype-1a and -1b Replicons as well as Replicons Carrying NS3 Protease or NS5A Protein from Patient Isolates
November 7
8:00 a.m. – 5:30 p.m.
High Rapid Virologic Response(RVR) with ACH-1625 Daily Dosing plus PegIFN-alpha 2a/RBV in a 28-day Phase 2a Trial

"As we look toward the upcoming AASLD meeting in November, we continue to work toward our goal of delivering on a number of significant milestones for Achillion. Our focus remains on reporting top-line Phase 2 12-week EVR results for ACH-1625 in combination with pegylated-interferon and ribavirin for the treatment of genotype 1 treatment-naïve HCV, and realizing proof-of-concept Phase 1 results for both ACH-2684 against HCV genotypes 1 and 3, and ACH-2928 against genotypes 1a and 1b, all near the end of this year," commented Michael D. Kishbauch, President and Chief Executive Officer of Achillion.

Abstracts can be accessed at the AASLD website at http://www.aasld.org.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including statements with respect to the potency, safety and other characteristics of Achillion's NS5A inhibitors, which may not be duplicated in clinical studies, and Achillion's expectations regarding results, timing and duration of clinical trials and reporting of results from clinical trials of ACH-1625, ACH-2684 and Achillion's NS5A inhibitors, including ACH-2928. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are Achillion's ability to complete the development of its drug candidates under the timelines it anticipates in current and future clinical trials; to obtain patent protection for its drug candidates, and the freedom to operate under third party intellectual property; to establish commercial manufacturing arrangements and to identify, enter into and maintain collaboration agreements with appropriate third-parties; and to raise the capital needed to achieve its business objectives. These and other risks are described in the reports filed by Achillion with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and its subsequent SEC filings.

In addition, any forward-looking statement in this press release represents Achillion's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Achillion disclaims any obligation to update any forward-looking statement, except as required by applicable law.

CONTACT: Company Contact:
         Glenn Schulman
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 752-5510
         gschulman@achillion.com
         
         Investors:
         Mary Kay Fenton
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         mfenton@achillion.com
         
         Media:
         Christin Culotta Miller
         Ogilvy PR
         Tel. (646) 229-5178
         christin.miller@ogilvypr.com
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here

Portions of this content may be copy written by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. SmartReadMX and other related related technologies used to produce content for this service are covered by US Patents numbers 7,865,496, 7,856,390, and 7,716,116.